# EDGAR Filing Document

**Accession Number:** 0000921114
**File Stem:** 0000000000-25-008642
**Filing Date:** 2025-8
**Character Count:** 2418
**Document Hash:** 7c0fb94e90e04efb8cbd1479e96957ff
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-008642.hdr.sgml**: 20250922

**ACCESSION NUMBER**: 0000000000-25-008642

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250815

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Armata Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0000921114
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 911549568
- **STATE OF INCORPORATION:** WA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-289585

**BUSINESS ADDRESS:**
- **STREET 1:** 5005 MCCONNELL AVE
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90066
- **BUSINESS PHONE:** 310-665-2928

**MAIL ADDRESS:**
- **STREET 1:** 5005 MCCONNELL AVE
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90066

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AmpliPhi Biosciences Corp
- **DATE OF NAME CHANGE:** 20130222

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TARGETED GENETICS CORP /WA/
- **DATE OF NAME CHANGE:** 19940331
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001104659-25-077648

## Text-Extract

```

                                                           August 15, 2025

Deborah L. Birx, M.D.
Chief Executive Officer
Armata Pharmaceuticals, Inc.
5005 McConnell Avenue
Los Angeles, California 90066

       Re: Armata Pharmaceuticals, Inc.
           Registration Statement on Form S-3
           Filed August 13, 2025
           File No. 333-289585
Dear Deborah L. Birx M.D.:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Chris Edwards at 202-551-6761 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:   Andrew C. Marmer

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._